← Back to Clinical Trials
Recruiting NCT06195059

NCT06195059 Contrast Echocardiography During Exercise to Assess Pulmonary Blood Volume

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06195059
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Heart Failure
Study Type OBSERVATIONAL
Enrollment 800 participants
Start Date 2024-07-30
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 800 participants in total. It began in 2024-07-30 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate whether pulmonary blood volume (PBV) derived from contrast echocardiography can serve as a non-invasive surrogate for invasive pulmonary artery wedge pressure (PAWP) during exercise. Also, to compare changes in PBV with exercise in patients with and without heart failure and pulmonary vascular disease.

Eligibility Criteria

Inclusion Criteria: * Patients referred to the cardiac catheterization laboratory for invasive exercise right heart catheterization for evaluating exertional dyspnea. Investigators will include patients with normal or low EF, and across the spectrum of pulmonary hypertension severity. Exclusion Criteria: * Patient inability or unwillingness to undergo echocardiography including a contrast method, or if echocardiography would, in the opinion of the investigator, somehow compromise the quality of data acquisition for the clinical case. * Prior adverse reaction to echo contrast administration

Contact & Investigator

Central Contact

Circulatory Failure Research Team

📞 507-255-2200

Principal Investigator

Barry Borlaug, MD

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT06195059 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06195059 currently recruiting?

Yes, NCT06195059 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.

Where is the NCT06195059 trial being conducted?

This trial is being conducted at Rochester, United States.

Who is sponsoring the NCT06195059 clinical trial?

NCT06195059 is sponsored by Mayo Clinic. The principal investigator is Barry Borlaug, MD at Mayo Clinic. The trial plans to enroll 800 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology